Acer therapeutics secures up to $48.5 million in convertible note and secured loan financing facilities

Newton, mass., march 07, 2022 (globe newswire) -- acer therapeutics inc. (nasdaq: acer), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into convertible note and loan financing facilities for up to $48.5 million with affiliates of marathon asset management l.p. (marathon) and swk holdings corporation (nasdaq: swkh), subject to certain conditions. proceeds from these financings would be used to advance acer's pipeline.
ACER Ratings Summary
ACER Quant Ranking